Evaluating Intercostobrachial Nerve Block's Effect on Pain Control After Shoulder Replacement

Launched by UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER · Sep 15, 2023

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients 18-80 years old
• • Adult patient's BMI \<= 35
• • Individuals presenting for primary total shoulder arthroplasty or reverse total shoulder arthroplasty
• • Anticipated discharge home same day of surgery
• • Patient is able to provide informed consent to participate in the study.
• Exclusion Criteria:
• • Patient presenting for revision shoulder surgery
• • Allergy to amide local anesthetic, liposomal bupivacaine or other medication involving liposomal formulation
• • Preexisting neurological deficits involving or potentially involving the ipsilateral brachial plexus
• • Preexisting contralateral vocal fold paralysis or recurrent laryngeal paralysis
• • Psychiatric or cognitive disorders that could interfere with perioperative evaluation including drug or alcohol abuse
• • Chronic pain conditions
• • Preoperative opioid use
• • Moderate to severe pulmonary disease
• • Moderate to severe sleep apnea
• • Planned postoperative admission.
• • Unplanned postoperative admission
• • Any contraindication to interscalene or intercostobrachial nerve block including any local disorder of the skin where blockade is to be performed which would prevent safe performance of the block
• • Any coagulation abnormality which would be a contraindication for block placement
• • Preoperative chronic renal dysfunction requiring renal replacement therapy or CrCl \< 60
• • Sulfa allergy (or other reason patient cannot receive celecoxib)
• • Allergy or intolerance to any medication in the protocol
• • Body mass index \>35
• • Pregnancy
• • Incarceration
• • ASA classification greater than 3
• • Inability to provide informed consent
• • Refusal to participate in the study